News and Announcements
SUDA Annual Report to Shareholders 2016
- Published September 23, 2016 4:50PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
22nd September 2016, ASX Announcement
Letter From The Chairman
“Our global reputation in oro-mucosal drug delivery is growing as we continue to generate new discussion with potential partners as well as progressing existing discussions along the project cycle.”
Looking at the share price over the last 15 months suggests that the 2015-16 year was not a good year for SUDA, or for our shareholders. We continue to be very conscious of our shareholders’ expectations and anticipation of finalising licensing or sale agreements.
I would like to take this opportunity to provide further insight into our project developments, our achievements and our business development over the year.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
